FindTrial
Sign In

Best Standard of Care

OTHER6 trials

Sponsors

Valerio Therapeutics, NovoCure Ltd., NovoCure GmbH, Medical University of Vienna, Hofseth Biocare ASA

Conditions

1-5 Brain Metastases From Non-Small Cell Lung CancerBrain Metastases From Non-small Cell Lung Cancer (NSCLC)COVIDCOVID-19Carcinoma, HepatocellularCovid-19NSCLC Brain Metastasis

Phase 2

Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET)
NCT01755624
NovoCure Ltd.1-5 Brain Metastases From Non-Small Cell Lung Cancer
Start: 2013-01-31End: 2017-07-31Updated: 2016-09-21
Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)
NCT04351724
Medical University of ViennaCOVID-19
Start: 2020-04-16End: 2022-03-31Target: 500Updated: 2021-03-02

Phase 3

Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma
CompletedNCT01655693
Valerio TherapeuticsCarcinoma, Hepatocellular
Start: 2012-06-30End: 2019-05-31Updated: 2021-06-02
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
CompletedNCT02831959
NovoCure GmbHBrain Metastases From Non-small Cell Lung Cancer (NSCLC)
Start: 2016-07-31End: 2024-11-29Updated: 2025-10-31

Unknown Phase

Investigation of the Efficacy of CARDIO Softgels PLUS Best-standard-of-care in the Recovery of Patients With COVID-19
CompletedNCT04465513
Hofseth Biocare ASACOVID, Covid-19
Start: 2020-08-31End: 2021-10-04Updated: 2021-10-05
Tumor Treating Fields (TTF) in Combination with Stereotactic Radiosurgery(SRS) for Brain Metastases from Non-small Cell Lung Cancer.
Not yet recruitingNCT06716775
Jiangsu Healthy Life Innovation Medical Technology Co., LtdNSCLC Brain Metastasis
Start: 2024-12-20End: 2028-10-30Target: 200Updated: 2024-12-04

Related Papers

Tumor Treating Fields Therapy After Stereotactic Radiosurgery for Brain Metastases From Non-Small Cell Lung Cancer: Final Results of the Phase 3 METIS Study.
2025-09-291 citations
Visualizing a marker's degrees of necessity and of sufficiency in the predictiveness curve.
2025-04-23
Results from METIS (EF-25), an international, multicenter phase III randomized study evaluating the efficacy and safety of tumor treating fields (TTFields) therapy in NSCLC patients with brain metastases.
Journal of Clinical Oncology2024-06-0115 citations
RTID-06. THE PIVOTAL METIS (EF-25) STUDY OF TUMOR TREATING FIELDS (TTFIELDS) THERAPY FOR BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING RADIOSURGERY
Neuro-Oncology2023-11-01
Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE - COALITION VIII randomised clinical trial.
2023-05-1812 citations
Computational Analysis of Tumor Treating Fields for Non-Small Cell Lung Cancer in Full Thoracic Models.
2023-02-266 citations
Experiences and challenges faced by patients with COVID-19 who were hospitalised and participated in a randomised controlled trial: a qualitative study
BMJ Open2022-10-018 citations
CLRM-10 METIS (EF-25): A PIVOTAL, RANDOMIZED CONTROLLED STUDY OF TUMOR TREATING FIELDS IN PATIENTS WITH 1–10 BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER
Neuro-Oncology Advances2022-08-01
Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)
Frontiers in Pharmacology2022-07-2215 citations
A Model Predicting Mortality of Hospitalized Covid-19 Patients Four Days After Admission: Development, Internal and Temporal-External Validation
Frontiers in Cellular and Infection Microbiology2022-01-2416 citations
TAMI-04. TUMOR TREATING FIELDS (TTFIELDS) HINDER GLIOMA CELL MOTILITY THROUGH REGULATION OF MICROTUBULE AND ACTIN DYNAMICS
Neuro-Oncology2020-11-01
RTID-01. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS FOR BRAIN METASTASES (1-10) FROM NSCLC IN THE PHASE 3 METIS TRIAL
Neuro-Oncology2020-11-01
30. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS FOR BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS TRIAL
Neuro-Oncology Advances2020-08-011 citations
RBTT-02. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS FOR BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS TRIAL
Neuro-Oncology2019-11-011 citations
TRLS-01. RADIOSURGERY FOLLOWED BY TUMOR TREATING FIELDS (TTFIELDS) FOR BRAIN METASTASES (1–10) FROM NSCLC IN THE PHASE 3 METIS TRIAL
Neuro-Oncology Advances2019-08-01
Abstract CT172: Phase III METIS study: Tumor Treating Fields (150 kHz) and radiosurgery for supra- and/or infratentorial brain metastases (1-10) from non-small cell lung cancer (NSCLC)
Cancer Research2019-07-01
Abstract 4450: Novel transducer array layouts to optimize the treatment of multiple brain metastases with tumor treating fields
Cancer Research2019-07-01
Abstract 4450: Novel transducer array layouts to optimize the treatment of multiple brain metastases with tumor treating fields
Bioinformatics, Convergence Science, and Systems Biology2019-07-01
Abstract CT172: Phase III METIS study: Tumor Treating Fields (150 kHz) and radiosurgery for supra- and/or infratentorial brain metastases (1-10) from non-small cell lung cancer (NSCLC)
Clinical Trials2019-07-01
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.
2019-04-0435 citations

9 more papers not shown